Alternative Cancer Treatment
Google News
Updated: 22 hours 34 min ago
Medlab Clinical's NanaBis drug dramatically improves cancer bone pain for first patient group in treatment study - Small Caps
Categories: Cancer News
[Full text] The potential of radiotherapy to treat cancers | IJN - Dove Medical Press
[Full text] The potential of radiotherapy to treat cancers | IJN Dove Medical Press
Categories: Cancer News
[Full text] Bioactive Compounds and Traditional Herbal Medicine | DNND - Dove Medical Press
[Full text] Bioactive Compounds and Traditional Herbal Medicine | DNND Dove Medical Press
Categories: Cancer News
Nivolumab Plus Ipilimumab Demonstrates Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer - Cancer Network
Nivolumab Plus Ipilimumab Demonstrates Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer Cancer Network
Categories: Cancer News
These Popular Supplements Have Hidden Dangers, Warn Experts | Eat This Not That - Eat This, Not That
Categories: Cancer News
Nivolumab/Ipilimumab Showcases Significant Antitumor Activity in Metastatic CRPC - OncLive
Categories: Cancer News
Hutson Compares Avelumab for PD-L1 Positive Versus PD-L1 Negative Bladder Cancer - Targeted Oncology
Categories: Cancer News
Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021 - PRNewswire
Categories: Cancer News
Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021 - PRNewswire
Categories: Cancer News
Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021 - PRNewswire
Categories: Cancer News
Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021 - PRNewswire
Categories: Cancer News
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response - PharmiWeb.com
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response PharmiWeb.com
Categories: Cancer News
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet
Categories: Cancer News
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis - EurekAlert
Categories: Cancer News
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis - EurekAlert
Categories: Cancer News
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial - Business Wire
Categories: Cancer News
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial - Business Wire
Categories: Cancer News
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial - Business Wire
Categories: Cancer News
Antibiotics need further study in cancer treatments - Chicago Daily Herald
Antibiotics need further study in cancer treatments Chicago Daily Herald
Categories: Cancer News
